British scientists have hailed the “tremendously exciting” news that a US coronavirus vaccine may prevent 94.5% of people from getting Covid-19 - just days after Pfizer reported good results on its jab.
Interim data from the US firm Moderna suggests its vaccine is highly effective in preventing people getting ill and also works across all age groups, including the elderly.
The UK has not placed an order for the vaccine – which works in a similar way to Pfizer’s – and the British Government is currently working on getting access to stock.
A spokesman said: “Moderna are currently scaling up their European supply chain which means these doses would become available in spring 2021 in the UK at the earliest.”
Scientists said the news bodes well for other Covid-19 vaccines, with the one for Oxford University and UK pharmaceutical giant AstraZeneca due to report in the coming days or weeks.
Moderna intends to submit an application for an Emergency Use Authorisation with the US Food and Drug Administration shortly and will submit further data on the vaccine’s effectiveness and safety.
The firm’s final-stage clinical trial is ongoing and includes more than 30,000 people in the US.
The interim analysis included 95 participants with confirmed cases of Covid-19, of which 90 had received the placebo and five the active vaccine.
The 95 cases included 15 older adults – aged 65 and over. This included 20 people who were not white – including 12 of whom were from Hispanic or Latino/a backgrounds, four African Americans, three Asian Americans and one who was multiracial.
Severe cases of coronavirus were also examined, including 11 severe cases in the first interim analysis.
All 11 cases occurred in the placebo group and none in the group which had received the vaccine, known currently as mRNA-1273.
Moderna said its available safety data does not indicate any significant safety concerns.
The vaccine was generally safe and well tolerated, and the majority of adverse events were mild or moderate in severity, it said.
Severe events after the first dose included injection site pain and after the second dose included fatigue, myalgia (muscle pain), arthralgia (joint pain), headache, pain, and redness at the injection site.
But these effects of the injection were generally short-lived, Moderna said.
The 94.5% efficacy from this analysis could drop as further results from the clinical trial are announced.
Stephane Bancel, chief executive officer of Moderna, said: “This is a pivotal moment in the development of our Covid-19 vaccine candidate.
“Since early January, we have chased this virus with the intent to protect as many people around the world as possible.
“All along, we have known that each day matters.
“This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent Covis-19 disease, including severe disease.”
At the end of October, Moderna announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has started the rolling review process of its vaccine.
This means the MHRA will review data as it becomes available from ongoing studies, with the ability to at some point say whether the vaccine should be licensed in the UK.
The announcement comes one week after Pfizer/BioNTech released interim study data suggesting their vaccine is more than 90% effective.
Peter Openshaw, professor of experimental medicine at Imperial College London, said: “This news from Moderna is tremendously exciting and considerably boosts optimism that we will have a choice of good vaccines in the next few months.
“First we heard 90% efficacy from Pfizer and BioNTech, then the Russians said 92% and now Moderna says 94.5%.
“This latest press release is based on a study of 30,000 US adults, including many high-risk or elderly persons.
“This gives us confidence that the results are relevant in the people who are most at risk of Covid-19 and in most need of the vaccines.
“Moderna have also announced that the vaccine can be kept in a conventional freezer (-20C) for up to six months, and that once thawed the vaccine can be kept for up to 30 days at standard refrigerator (2 to 8C). This makes the vaccine much easier to deliver.”
Stephen Evans, professor of pharmacoepidemiology at the London School of Hygiene and Tropical Medicine, said: “This announcement from Moderna is a further encouragement that vaccines will be found to not only have an acceptable efficacy, but an efficacy that is much greater than we had anticipated.
“As with previous announcements, this is encouraging for other vaccines that may be expected to also have worthwhile efficacy.
“Although they reported efficacy being over 94%, there is statistical uncertainty in this, but based on these data, the likely efficacy will be better than 85% which would be greater than most scientists would have expected.
“This is the first study to report on severe cases and while uncertainty remains, the finding of no severe cases with the vaccine and 11 cases with placebo is very strong evidence that the vaccine prevents severe as well as mild disease.”
He said more data was needed on the elderly “but this is definitely encouraging progress”.
Professor Trudie Lang, from the University of Oxford, said: “It is very good news indeed to see another vaccine coming through with similar efficacy results as were reported last week from Pfizer.”
She added: “These early results suggest that there was a representation across different age groups and diverse communities in the protected group.
“This is really encouraging and it further demonstrates that a vaccine for Covid is a real probability and that having more than one supplier should help assure better and more equitable global availability.”
A government spokesperson said: “The news from Moderna appears to be good and represents another significant step towards finding an effective COVID19 vaccine. As part of the ongoing work of the Vaccines Taskforce, the Government is in advanced discussions with Moderna to ensure UK access to their vaccine as part of the wider UK portfolio."